WO2000078977A1 - Novel vectors for improving cloning and expression in low copy number plasmids - Google Patents
Novel vectors for improving cloning and expression in low copy number plasmids Download PDFInfo
- Publication number
- WO2000078977A1 WO2000078977A1 PCT/US2000/016767 US0016767W WO0078977A1 WO 2000078977 A1 WO2000078977 A1 WO 2000078977A1 US 0016767 W US0016767 W US 0016767W WO 0078977 A1 WO0078977 A1 WO 0078977A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vector
- copy number
- plasmid
- gene
- bac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
Definitions
- Vectors such as cosmids, yeast artificial chromosomes (YACs), and bacterial artificial chromosomes (BACs) permit the construction of large insert genomic DNA libraries.
- libraries have served a pivotal role for the isolation and characterization of important genomic regions and genes from a variety of organisms including bacterial, archaea, mammals etc.
- the bacterial artificial chromosome (BAC) system is emerging as the system of choice for constructing libraries with DNA inserts up to 300 kilobases.
- a major advantage of BACs is that plasmids containing large inserts can be efficiently transformed by electroporation and propagated in E. coli.
- the low copy number of the BAC vector (1-2 per cell ), is thought to contribute to the stability of large BACs over many generations, as compared to multi-copy counterparts (Kim et al, NAR, 20(5):1083-1085).
- the popular BAC vector pBeloBAC1 1 (Research Genetics) is derived from the endogenous E. coli F plasmid.
- the F backbone contains four essential regions that play a role in plasmid stability and copy number.
- parA and B are required for partitioning and plasmid stability functions.
- parB is also required for incompatibility with regard to other F factors.
- OriS is the origin of F plasmid DNA replication, which is unidirectional.
- repE encodes protein E, essential for replication from OriS and for copy number control.
- a chloramphenicol resistance gene was incorporated for antibiotic selection of transformants.
- pBeloBAC1 1 encodes the lacZ gene, and thus the identification of recombinant DNA clones is simplified by blue/white selection.
- the most widely used E. coli strain for BAC cloning is DH10B (Grant et al. 1990. PNAS 87:4645).
- BAC plasmids are most popularly used for genome mapping, positional cloning, and DNA sequencing. One can also analyze expression of heterologous activities encoded by a BAC insert. Whereas the single copy nature of BAC vectors contributes to insertion stability, this same property is usually a liability for purifying and sequencing BAC DNA.
- a large volume of culture is needed to obtain enough plasmid DNA for conventional uses. The large volume introduces significant chromosomal DNA contamination of plasmid preparations, which often interferes with subsequent manipulations of the vector, including DNA sequencing reactions. To minimize co-purification of chromosomal DNA, conventional DNA isolation protocols must be considerably modified and therefore are not easily amenable to high-throughput protocols for plasmid DNA isolation and sequencing.
- An additional potential liability of the single copy BAC vector relates to expression of heterologous DNA in E. coli. Expression can be limited by single plasmid copy number, especially if expression is reliant on foreign promoters present in the heterologous insert.
- Our invention provides methods that facilitate 1 )cloning of large inserts into BAC plasmids 2) isolation of large amounts of BAC DNA (by increasing plasmid copy number), and 3)increasing heterologous expression from BAC plasmid inserts (by increasing plasmid copy number and/or introducing promoters into the insert).
- Cloning and sequencing of large DNA fragments has become increasingly necessary as more researchers enter the field of genomics. Although many vectors and tools are available for these tasks, such vectors are often low copy so that the large DNA inserts are stably maintained within the vector.
- a major impediment to the use of low copy number vectors is the difficulty in preparing large quantities of vector for cloning and sequencing. In particular, automated sequencing techniques are not adapted for use with low copy vectors. Expression of gene products encoded by large DNA inserts may also suffer due to the low copy number of the vectors.
- the invention described herein provides novel vectors for improving cloning, sequencing and expression of DNA inserts in low copy vectors.
- the invention provides a vector for increasing the copy number of plasmids, comprising a transposable element containing a moderate or high copy number origin of replication capable of in vitro transposition into a target plasmid.
- the target plasmid is a single or low copy plasmid, e.g. a BAC vector, that is useful for cloning large pieces of DNA.
- the transposon plasmid may contain any moderate or high copy origin of replication that is compatible with a bacterial host such as E. coli.
- an exemplary ori is the colEI ori from pBR322. Expression of gene products encoded by the DNA inserts is facilitated by addition of a transcription control sequence to the transposable element.
- the transcription control sequence is the T7 promoter, which is functional in cells expressing the T7 RNA polymerase.
- Other promoters that are useful for increasing expression of cloned genes include endogenous bacterial promoters.
- the vectors may further comprise one or more antibiotic resistance genes, such as those for ampicillin, tetracycline or kanamycin.
- they may contain a counterselectable marker, such as the sacB gene from ⁇ . subtilis, to insure that only transformants which take up the target plasmid will survive.
- one such vector may comprise
- vectors may contain a transcription control sequence in addition to the above components.
- One exemplary vector is pTRANS-sac ⁇ , which contains (a) a transposable element containing a pBR322 origin of replication, (b) a kanamycin resistance gene, (c) a B. subtilis sacB gene, and (d) a T7 promoter.
- a vector comprising (a) a transposable element containing a high copy number origin of replication, (b) an antibiotic resistance gene, and (c) a transcription control sequence.
- An exemplary vector of this type is pTRANS, which contains (a) a transposable element containing a pBR322 origin of replication, (b) a kanamycin resistance gene, and (c) a T7 promoter.
- the invention also provides methods for using such transposon plasmids.
- the invention provides a method for increasing the copy number of a target plasmid comprising: mixing, in vitro, the target plasmid with any of the vectors described above under conditions permitting introduction of the high copy number origin of replication into the target plasmid.
- the invention thus provides a method for sequencing a gene in a low copy number plasmid, comprising mixing, in vitro, the target plasmid with a transposon vector of this invention, transforming the mixture and determining the sequence of genes isolated from selected transformants.
- Transformants which have the transposon introduced into a useful locus in the target plasmid may be screened for by detecting a phenotypic change in the clones transformed with the mixture relative to clones transformed with BAC vector alone. Phenotypic changes that may be observed include an increase or decrease in gene expression.
- Vectors containing transcription control sequences may be used to increase expression of a gene in a target plasmid by mixing such vectors in vitro with a target plasmid and then transforming the mixture into cells capable of recognizing the transcription control element and expressing the gene.
- a target plasmid into which a transposon containing a T7 promoter has been introduced may be transformed into cells expressing T7 polymerase.
- the plasmids of this invention also facilitate full length cloning of genes, e.g. those isolated from a plurality of organisms or from a genomic source.
- the method for full length cloning of genes comprises mixing a BAC library with a transposon plasmid of this invention to increase the copy number of the plasmids, and then isolating large amounts of DNA and cloning full length genes.
- the invention provides a method for generating a shuttle vector comprising mixing, in vitro, a target plasmid with a vector comprising a transposable element containing an origin of replication for a host different from that of the target plasmid, under conditions permitting transposition of the ori into the target plasmid.
- the ori may be a moderate or high copy number ori.
- the invention provides improved BAC vectors which facilitate cloning of large DNA fragments into low copy vectors.
- These improved BAC vectors comprise a high copy origin of replication flanked by cleavage sites for a restriction enzyme, wherein cleavage of the vector with the restriction enzyme leaves single base extensions for cloning and removes the high copy origin of replication.
- the vectors further comprise a BST X1 site.
- An exemplary vector of this type is pBacTA.PUC2.
- FIG. 1 Plasmid pGPSI . Commercially available transposon plasmid from New England Biolabs.
- Plasmid pTRANS-SacS The transposable region contains sequences encoding a T7 promoter, a lacl gene, a pBR322 origin of replication and a kanamycin resistance gene. Plasmid pTRANS-SacS also encodes a counter- selectable marker, the B. subtilis sacB gene, located outside of the transposable region. Expression of sacB, encoding the enzyme levansucrase, is lethal to E. coli in the presence of 5% sucrose. Pj7, T7 promoter; lac I, lac repressor gene; pBR322 ori, origin of replication from plasmid pBR322; SacB, B. subtilis sacB gene.
- Plasmid pTRANS The transposable region contains sequences encoding a T7 promoter, a lacl gene, a pBR322 origin of replication and a kanamycin resistance gene. Plasmid pTRANS is identical to pTRANs-SacS except for the absence of the counter-selectable marker, the ⁇ . subtilis sacB gene. Pj7, T7 promoter; lacl, lac repressor gene; pBR322 ori, origin of replication from plasmid pBR322; SacB, B. subtilis sacB gene.
- Figure 4 Schematic of protocol for in vitro transposition reaction containing pTRANS-Sac ⁇ (transposon donor) and pBeloBACII (recipient or target plasmid containing a DNA insert).
- sucrose-R resistant to 5% sucrose
- sucrose-S sensitive to 5% sucrose
- kan-R resistant to 50 micrograms/ml kanamycin
- kan-S sensitive to 50 micrograms/ml kanamycin
- chlor-R resistant to 10 micrograms/ml chloramphenicol
- chlor-S sensitive to 10 micrograms/ml chloramphenicol, Pj7,
- T7 promoter lac I, lac repressor
- pBR322 ori origin of replication from plasmid pBR322
- SacB B. subtilis sacB gene.
- Figure 5 Amplification of lipase expression from a BAC clone by increasing copy number with pTRANS-Sac ⁇ .
- Figure 6 Amplification of pigment expression from a BAC clone by increasing copy number with pTRANS-Sac ⁇ .
- BACTAPUC1 (pBTP1 ) - Diagram of modified pBeloBAC1 1.
- the original vector was altered by including a modified polylinker region into which a high-copy PUC vector was inserted.
- a unique ohgonucleotide adaptor we have introduced the ability to utilize cloning based on single base extensions.
- FIG. 9 pBTP3- Illustration of an adaptor system which will allow for more efficient ligation
- a BstXI restriction site is engineered into the vector such that only the appropriate modified insert (ligated with complementary adaptors) will ligate.
- Figure 10 Illustration of random insertion of promoters into metagenomic library using a modified tn5 transposon .
- the boxed figure at the bottom represents the optimum insertion pattern.
- an “antibiotic resistance gene” is a gene which encodes a protein that confers on a cell resistance to one or more specific antibiotics.
- a "coding sequence” or a sequence which "encodes” a particular polypeptide or RNA is a nucleic acid sequence which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vitro or in vivo when placed under the control of an appropriate expression control sequence.
- the boundaries of the coding sequence are generally determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus.
- a coding sequence can include, but is not limited to, cDNA from procaryotic or eukaryotic mRNA, genomic DNA sequences from procaryotic or eukaryotic DNA, and synthetic DNA sequences.
- a transcription termination sequence will usually be located 3' to the coding sequence.
- a “construct”, e.g., a “nucleic acid construct” or “DNA construct”, refers to a nucleic acid or nucleic acid sequence.
- Copy number refers to the number of copies of a vector present in a cell, which is determined by its origin of replication. A vector with a low copy number exists in less than five copies in the cell, most often in only a single copy. Moderate copy number vectors, such as those with a pBR322 ori, exist in about 20-40 copies per cell, usually about 30 copies. High copy number vectors, e.g., pUC based vectors, exist in about 100 or more copies per cell.
- a "counterselectable marker” is a gene or genes encoding a property that is lethal or inhibitory to cell growth. Lethality or growth inhibition may result, e.g., from 1 ) induction of expression of the gene or genes, 2) constitutive expression of a gene(s) which is toxic under certain growth conditions, 3) growth in the presence of a toxic drug or chemical (in the absence of a resistance gene).
- Examples of counter-selectable markers are: sacB gene, inhibits growth of E. coli in the presence of 5% sucrose; phage lysis genes, expression of phage lysis genes (such as lambda phage lysis genes) kills E.
- F-plasmid cc ⁇ f ⁇ gene expression of ccdB gene kills E. coli by inhibiting DNA gyrase
- colicin release genes such as the kil gene for colicin E1 ), expression of kil gene kills E. coli.
- Gene refers to a nucleic acid molecule or sequence comprising an open reading frame and including at least one exon and (optionally) one or more intron sequences.
- Nucleic acid refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA).
- DNA deoxyribonucleic acid
- RNA ribonucleic acid
- the term should also be understood to include derivatives, variants and analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides.
- oil of replication or "ori” is a sequence of DNA at which replication is initiated.
- a "shuttle vector” is a vector that is able to replicate in more than one type of host cell. Typical shuttle vectors contain two origins of replication.
- Transcription control sequence refers to DNA sequences, such as initiation signals, enhancers, promoters and silencers, which induce or control transcription of DNA sequences with which they are operably linked. Control elements of a gene may be located in introns, exons, coding regions, and 3' flanking sequences.
- control elements are "tissue specific", i.e., affect expression of the selected DNA sequence preferentially in specific cells (e.g., cells of a specific tissue), while others are active in many or most cell types. Gene expression occurs preferentially in a specific cell if expression in this cell type is observably higher than expression in other cell types.
- Control elements include so-called “leaky” promoters, which regulate expression of a selected DNA primarily in one tissue, but cause expression in other tissues as well.
- a control element can act constitutively or inducibly.
- An inducible promoter for example, is demonstrably more active in response to a stimulus than in the absence of that stimulus.
- a stimulus can comprise a hormone, cytokine, heavy metal, phorbol ester, cyclic AMP (cAMP), retinoic acid or derivative thereof, etc.
- Transposable element or “transposon” refers to a DNA sequence able to move or “hop” from its original location and insert itself into a new location within new DNA sequence.
- the new site of insertion is a base sequence with which the element has no homology.
- Hopping is not dependent on bacterial recombination functions.
- vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
- One type of vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Often vectors are used which are capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of an included gene operatively linked to an expression control sequence can be referred to as "expression vectors".
- Expression vectors are typically in the form of "plasmids" which refer generally to circular double stranded DNA loops which, in their vector form are not bound to the chromosome. In the present specification, "plasmid” and “vector” are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of vectors which serve equivalent functions and which are or become known in the art.
- Plasmids encoding a moderate or high copy origin of replication transposon facilitate use of BAC vectors and other low copy number vectors useful for research in which large cDNA or genomic inserts must be cloned into vectors. For example, in genomics research, large fragments of the genome are cloned into vectors for sequencing or expression.
- Low copy vectors which can be used as target plasmids for the purposes of this invention are those vectors which contain very low copy oris (1-2 copies/cell), such as bacteriophage P1 , F plasmid and R1 plasmid, or low copy oris, such as plasmid pSC101 (about 5 copies per cell), plasmid p15A (10-12 copies per cell) or plasmid RK2 (4-7 copies per cell.)
- One object of the invention is to provide a vector comprising a transposable element which is capable of random in vitro transposition into a target plasmid.
- the plasmids of this invention contain a moderate or high copy number origin of replication (hereafter referred to as an ori) within the transposable sequence.
- Transposon plasmids are known in the art. Such plasmids have been used to facilitate sequencing reactions by "hopping" into random sites in a target plasmid. Since the transposon ends can be used to prime sequencing reactions, the number of primers required for sequencing is reduced, and the necessity of sequencing overlapping ends in order to generate new sets of primers is eliminated. Using transposon vectors, one can sequence large numbers of clones simultaneously using a single set of primers.
- transposon plasmids used for sequencing generally contain a defective origin of replication which cannot replicate in wild type bacterial cells, whereas the plasmid of this invention contain a high copy origin of replication within the transposable sequence.
- the transposition of the high copy ori into the target plasmid allows the target plasmid to replicate to high copy number within the host cell.
- Other plasmids are known which contain transposable oris which are useful in certain applications involving in vivo cloning. In those cases, the transposon hops into the chromosome, bringing with it the high copy ori.
- the gene and high copy ori are either excised with restriction enzymes or packaged into phage.
- Recircuiarization of the excised or packaged piece is then required to provide a plasmid which can replicate in high copy. Additionally, if the practitioner then desired to sequence genes cloned with these transposon plasmids, the genes would need to be subcloned into a sequencing vector. In contrast, the plasmids of this invention can transpose in vitro into a low copy number vector to insert a moderate or high copy ori. This improvement is particularly significant in a number of very important applications, such as are described below. Using these plasmids, a second recircuiarization step is not necessary: insertion of the transposon alone provides the target plasmid with the ability to replicate at high copy number permitting sequencing without the need for additional subcloning.
- Origins of replication to be used in the plasmids of this invention may be moderate copy, such as the colEI ori from pBR322 (15-20 copies per cell) or the R6K plasmid (15-20 copies per cell), or may be high copy, e.g. pUC oris (500-700 copies per cell), pGEM oris (300-400 copies per cell) pTZ oris (>1000 copies per cell) or pBluescript oris (300-500 copies per cell).
- the origins of replication in the transposon may be functional in E. coli or in any other prokaryotic cell type, such as Bacilli (e.g., ⁇ . subtilis) or Streptomycetes.
- the plasmids may further contain an antibiotic resistance gene within the transposable sequence, for selection on antibiotic-containing plates.
- antibiotic resistance genes are genes for resistance to ampicillin, kanamycin, tetracycline, chloramphenicol, etc.
- the plasmid may contain any one or more of such antibiotic resistance genes.
- the plasmids may contain one or more transcription control sequences.
- One such sequence should be found within the transposable sequence, such that when the transposon hops into the target plasmid, it carries along with it the transcription control sequence.
- An exemplary sequence is the T7 promoter, but any promoter or enhancer that is functional in prokaryotic cells may be used.
- Useful promoters include, but are not limited to, lac (E. coli ), trp (E. coli ), araBAD (E. coli ), tetA (E. coli ), tac, hybrid, (E. coli ), trc, hybrid (E. coli ), Ipp-lac hybrid (E. coli ), p
- the plasmids may also contain a counterselectable marker, which is outside of the transposable sequence.
- a counterselection marker ensures that any transformant that has received the original transposon plasmid will be selected against, since the counterselectable marker causes lethality in the host cell.
- the counterselectable marker can be the sacB gene from B. subtilis. When cells expressing sacB are grown on sucrose containing medium, sucrose polymers are formed which are toxic to the cells.
- Other counterselectable markers useful in this invention are phage lysis genes
- colicin release genes such as the kil gene for colicin E1 .
- the transposon plasmid is pTRANS-sac ⁇
- pGPSI transposon plasmid
- New England Biolabs Fig. 1
- pGPSI contains a defective origin of replication which is non-functional in wild- type E. coli. It also contains universal primer sites for DNA sequencing at both ends of the transposable element.
- pGPSI contains a defective origin of replication which is non-functional in wild- type E. coli. It also contains universal primer sites for DNA sequencing at both ends of the transposable element.
- a moderate copy origin of replication (the pBR322 ori) has been introduced into the transposon ("trans").
- Universal primer sites for DNA sequencing are encoded at both ends of trans and a T7 promoter, directed "outward" (i.e., away from the transposable element), is encoded on one end.
- the plasmid also contains the ⁇ . subtilis sacB gene for counterselection. In vitro transposition of trans into a single copy BAC vector introduces a moderate copy ori, thereby increasing the copy number of the target BAC vector.
- Transposon mutagenesis with pTRANS-sacB increases BAC vector copy number and facilitates automated DNA isolation and sequencing.
- pTRANS-Sac ⁇ has successfully been used to sequence large soil BAC plasmids containing greater than >30 kb DNA using automated DNA isolation and sequencing methods. Automated plasmid isolation and automated sequencing is not possible with single copy plasmids, therefore plasmids of this invention such as pTRANS-Sac ⁇ are valuable tools for automated DNA sequencing of single or low copy plasmids containing large inserts.
- Plasmid pTRANS-sacB as a tool for increasing heterologous gene expression from a given BAC plasmid or a pooled BAC library. a) Increasing expression through increasing plasmid copy number.
- Increasing the copy number of a given BAC plasmid or a BAC library is one way to increase heterologous gene expression and may allow for detection of new activities previously too low to detect from single copy plasmids. Subjecting either a given BAC clone or a pooled BAC library to transposon mutagenesis using the transposon plasmids described herein will increase the copy number of the BAC plasmids. In the case of a pooled BAC library, the resulting DNA library, containing random trans insertions can then be transformed into E. coli and the resulting transformants screened for new activities.
- Transposition of trans into a given BAC plasmid has been shown to increase heterologous expression from that BAC plasmid.
- Increased expression of heterologous activities allows one to overproduce the activity, greatly facilitating biochemical analysis of the activity.
- the library contains DNA inserts from a plurality of organisms.
- transposition of trans into a BAC library of DNA isolated from soil, followed by transformation into E. coli essentially generates a new library with increased copy number, potentially permitting detection of new activities not previously detectable from the low copy version of the library.
- This procedure allows one to first clone a large insert library in a more stable, low copy vector, and then increase the copy number when it is desirable.
- Transposition of trans into a given clone encoding a biosynthetic gene cluster may disrupt that gene cluster in such a way as to produce a new biological activity. Since biosynthesis of natural products such as polyketides is a stepwise enzymatic process, disruption of a gene encoding an intermediate step permits accumulation of a biosynthetic intermediate which may have a novel biological activity (that one may never otherwise have seen had the cluster remained intact). Increased copy number may permit overproduction of this activity, facilitating its detection, as described in Examples 4 and 5.
- the transposon directed insertion of high copy origins of replication can modify plasmid copy number, host utilization and level of production of molecules encoded within the foreign DNA inserts.
- transcription and expression of genes from other organisms phylogenetically distant from the E. coli host strain may be below the level of detection in subsequent screens.
- many natural products are encoded in multi-gene clusters with promoters running in both directions (see fig 5).
- a further application of this system utilizes a second transposon based system for the random introduction of multiple bacterial promoters which function in E. coli.
- the transposon system described above is based on Tn-7 bacterial transposon.
- This system has a characteristic termed "target immunity" which inhibits more than one transposable element within a 190kb contiguous strand of DNA (Anne E. Stellwagen and Nancy L. Craig Avoiding self: two Tn7-encoded proteins mediate target immunity in Tn7 transposition . EMBO J. 1997 16: 6823-6834.). Conversely, a transposon system based on Tn-5 has no such immunity system (Igor Yu Goryshin and William S. Reznikoff Tn5 in Vitro Transposition J. Biol. Chem. 1998 273: 7367-7374).
- Constructing a transposon based on this system and incorporating a strong bi-directional bacterial promoter (with or without a selectable marker) allows for the introduction of multiple transposons at random sites within a BAC library of DNA isolated from soil.
- a transposon/target ratio By controlling the transposon/target ratio, one may obtain a defined range of transposon insertions per single plasmid insert.
- a variation on this is to add a reporter gene such as GFP within the transposon and select bacteria (based on fluorescence) to obtain an optimum number of insertions where every additional GFP gene would cause an incremental increase in fluorescence detectable by standard flow cytometry. Many of the insertions will disrupt transcription, however the transposition is done multiple times on one library to obtain a large pool of randomly inserted promoters.
- BAC vectors stably accommodate large DNA inserts, they are often the vector of choice for genomic cloning. However, their low copy number often makes it difficult to isolate full length clones, since large numbers of cells would be required to provide a sufficient amount of DNA for cloning.
- Use of a vector which increases copy number e.g. pTRANS, can facilitate full-length cloning by allowing library construction in a BAC vector. Once the library is obtained, the copy number can be increased by using pTRANS or a similar vector, enabling cloning of full-length, large pieces of genomic DNA. 4) Construction of shuttle vectors:
- the plasmids of this invention allow expedited construction of shuttle vectors without the need for cloning.
- the transposon plasmid should contain an ori for expression in a host other than the host in which the target plasmid can replicate.
- the transposon may contain a B. subtilis ori, while the target plasmid contains an E. coli on.
- the resultant vector is able to replicate in both ⁇ . subtilis and E. coli.
- BAC vectors are widely used for cloning large DNA fragments (> 25 kb), it remains difficult to clone such large inserts.
- the improved BAC vectors of this invention contain modifications to traditional BAC vectors that improve cloning and make the vectors an increasingly useful tool in genomics research.
- the cloning vectors of this invention contain a high copy ori to facilitate large scale preparation of vector.
- the high copy ori is flanked by restriction sites, such that cloning of insert into the vector removes the high copy ori, restoring the vector to its original low copy number and improving stability of large DNA inserts. Additionally, cleavage of the vector with the restriction enzyme that removes the high copy ori leaves single base extensions on the vector.
- extensions facilitate cloning of large fragments of genomic DNA.
- Other modifications include the addition of BST X1 sites. The presence of this site allows the practitioner to increase the length of overhang on a genomic fragment by addition of BST X1 linkers. Generally, fragments of DNA with longer overhangs are easier to clone than those with single base extensions.
- Exemplary cloning vectors utilize plasmids which are based on the E. coli F-factor replicon.
- the F-factor replicon allows for strict copy number control of the clones so that they are stably maintained at 1 -2 copies per cell.
- the stability of the cloned DNA during propagation in an E. coli host is substantially higher in lower copy number vectors than in multi-copy counterparts (Kim et al, NAR, 20(5): 1083-1085).
- the stabilizing effect of BAC vectors is notable especially for certain genomic DNA that are normally unstable in high copy number vectors. This includes genomes of Archaeal, mammalian, or other origins.
- the pBeloBAC1 1 vector (a commercially available plasmid) allows lacZ- based positive color selection of the BAC clones that have insert DNA in the cloning sites at the time of library construction. There are several significant drawbacks to this vector. First, because the vector exists in single copy in E. coli, purifying the DNA in large quantity takes some effort. In addition, the available cloning sites are minimal and alternate cloning strategies are not possible.
- improved BAC vectors of this invention are exemplified by the vector pBacTA.pUC2, which contains several significant modifications to pBeloBAC1 1 : 1 ) a high copy pUC origin of replication is added to the vector to allow large scale vector purification in E. coli; 2) a restriction enzyme site flanks the pUC ori so that large inserts cloned into this site remove the high copy ori and allow the large DNA fragments to be stably inserted in a low copy vector 3) additional cloning sites have been introduced 4) single base extensions have been added to facilitate cloning.
- Plasmid pTRANS-sacB Plasmid pTRANS-sacB .
- the 4.2 kb Scal/Xbal fragment from pET-22b was cloned into plasmid pGPSI linearized with Spel and Swal.
- the resulting kanamycin-resistant plasmid, pTRANS (Fig. 3), encodes the trans transposon, containing the high copy ori and T7 promoter from pET-22b.
- a 1.7 kb sacB gene amplified from the B. subtilis 168 chromosome by PCR, was cloned into the unique Sacl site in pTRANS.
- the resulting plasmid, pTRANS-sac ⁇ (Fig. 2), can be counterselected in the presence of 5% sucrose.
- pTRANS-sac ⁇ and the target BAC plasmid would be mixed with transposase according to the New England Biolabs protocol, following the transposition reaction, the resulting DNA would be transformed into E. coli DH10B and plated on media containing kanamycin (to select for transpositions), chloramphenicol (to select for the BAC plasmid) and 5% sucrose (to counterselect pTRANS-sac ⁇ , which is lethal in the presence of sucrose).
- the resulting kanamycin/chloramphenicol/ sucrose-resistant plasmids should be BAC plasmids containing trans .
- Strain DH10B(DE3) was constructed using the DE3 lysogen kit from Novagen. Strain DH10B(DE3) expresses T7 RNA polymerase encoded by a chromosomal lysogen and is an expression host for plasmids driving heterologous expression from a T7 promoter.
- BACTAPUC1 The first version of the vector, pBTP1 , combines pBeloBAC with a high copy PUC-based vector. As shown in Fig 1 , insertion of an entire PUC plasmid into the cloning site accomplishes several things. First, it simplifies the purification of the vector prior to cloning by virtue of the high copy ori within the PUC insert which drives the copy number to >100 copies/cell. Second, by using a unique oligonucleotide adaptor, we have introduced additional cloning sites. This includes the ability to utilize cloning based on single base extensions.
- Thermostable polymerases such as Taq have a nontemplate-dependent activity which adds a single deoxyadenosine (A) to the the 3' end of DNA.
- This single base extended DNA will ligate efficiently with a vector that has corresponding deoxythymidine (T) ends.
- T deoxythymidine
- Ahdl GACNNNNNGTC
- DNA can be directly cloned without the need for partial restriction digestion. This latter point is key since cloning by partial restriction digestion will decrease the average insert size of the library by at least half (see below).
- FIG. 9 illustrates an example of one such system which uses a second degenerate restriction enzyme, BstXI (CCANNNNNNTGG).
- BstXI CACA 3'
- FIG. 9 illustrates an example of one such system which uses a second degenerate restriction enzyme, BstXI (CCANNNNNNTGG).
- BstXI CACA 3'
- Example 3 The Transposon Reaction
- the transposon reaction which is shown as a schematic in figure 4, uses buffers and enzymes supplied in the GPS-1 Genome Priming System kit supplied by New England Biolabs.
- 0.05 micrograms of pTRANS-Sac ⁇ is mixed with 0.2 micrograms of a BAC target plasmid.
- the reaction is carried out in 1X GPS1 buffer, in a total final volume of 20 microliters.
- 1 microliter of TnsABC* transposase is added to the plasmid mixture, the reaction mixed and incubated for 10 minutes at 370C.
- 1 microliter of start solution is then added and the reaction is mixed and incubated for 1 hour at 370C.
- the transposase is inactivated by incubating the reaction at 750C for 10 minutes.
- the inactivated reaction is dialyzed against water for 1 hour. 5 microliters of reaction is transformed, by electroporation, into E. coli cells such as DH10B or DH10B(DE3). Transformants are selected on LB plates containing kanamycin (50 micrograms/ml), chloramphenicol (10 micrograms/ml), and sucrose (5%).
- Example 4 Use of pTRANS to increase expression of lipase from a BAC clone
- the high-copy ori was hopped into a BAC plasmid containing a lipase gene isolated from soil DNA. This activity was originally very low level, and took ⁇ 1 week of incubation to detect.
- Lipase activity was detected (as shown in figure 4) by a clear halo surrounding bacterial colonies, indicating digestion of lipid in the media.
- Several transposon hop clones expressing lipase were chosen and restreaked onto a new LB chloramphenicol lipid agar plate to directly compare several high copy lipase overproducers (clones #3,4,5,6), a lipase knockout clone (#7) and the original low copy lipase-producing BAC (#2) versus a negative control (#1 ).
- the activity is readily detectable in only 2 days, demonstrating the utility of the transposon in increasing expression.
- Example 5 Use of pTRANS to increase expression of a purple pigment from a BAC clone
- the high-copy ori was hopped into a BAC plasmid containing a gene for a purple pigment isolated from soil DNA.
- a BAC plasmid containing approximately 25 kilobases of DNA isolated from a soil sample encoding a purple pigment, was subjected to a transposon reaction with pTRANS-Sac ⁇ , as described in Example 3. The reaction was transformed, by electroporation into DH10B cells and transformants were selected on LB plates containing kanamycin (50 micrograms/ml), chloramphenicol (10 micrograms/ml) and sucrose (5%).
- Figure 6 depicts two independent transposition events within MG1.1 , a single library clone which has been shown to produce a pigmented natural product. For comparison, also represented is a non-pigmented control and the original parent. As is evident from the figure, the introduction of the high copy pTRANS can increase the production of genes within a single clone by virtue of the increase in copy number. This affects both the overall levels of the pigment as well as accelerating the rate of pigment production.
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR0011765-0A BR0011765A (en) | 1999-06-18 | 2000-06-16 | Vectors to improve cloning and expression in low copy number plasmids |
| MXPA01012406A MXPA01012406A (en) | 1999-06-18 | 2000-06-16 | Novel vectors for improving cloning and expression in low copy number plasmids. |
| AU54966/00A AU5496600A (en) | 1999-06-18 | 2000-06-16 | Novel vectors for improving cloning and expression in low copy number plasmids |
| KR1020017016220A KR20020011139A (en) | 1999-06-18 | 2000-06-16 | Novel vectors for improving cloning and expression in low copy number plasmids |
| NZ515502A NZ515502A (en) | 1999-06-18 | 2000-06-16 | Novel vectors for improving cloning and expression in low copy number plasmids |
| EP00939961A EP1196613A1 (en) | 1999-06-18 | 2000-06-16 | Novel vectors for improving cloning and expression in low copy number plasmids |
| CA002375821A CA2375821A1 (en) | 1999-06-18 | 2000-06-16 | Novel vectors for improving cloning and expression in low copy number plasmids |
| JP2001505717A JP2003503029A (en) | 1999-06-18 | 2000-06-16 | Novel vectors for improved cloning and expression in low copy number plasmids |
| IL14712500A IL147125A0 (en) | 1999-06-18 | 2000-06-16 | Novel vectors for improving cloning and expressions in low copy number plasmids |
| NO20016153A NO20016153L (en) | 1999-06-18 | 2001-12-17 | New vectors to enhance cloning and expression in low copy number of plasmids |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14028799P | 1999-06-18 | 1999-06-18 | |
| US60/140,287 | 1999-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2000078977A1 true WO2000078977A1 (en) | 2000-12-28 |
Family
ID=22490577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2000/016767 Ceased WO2000078977A1 (en) | 1999-06-18 | 2000-06-16 | Novel vectors for improving cloning and expression in low copy number plasmids |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1196613A1 (en) |
| JP (1) | JP2003503029A (en) |
| KR (1) | KR20020011139A (en) |
| AU (1) | AU5496600A (en) |
| BR (1) | BR0011765A (en) |
| CA (1) | CA2375821A1 (en) |
| IL (1) | IL147125A0 (en) |
| MX (1) | MXPA01012406A (en) |
| NO (1) | NO20016153L (en) |
| NZ (1) | NZ515502A (en) |
| WO (1) | WO2000078977A1 (en) |
| ZA (1) | ZA200109441B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1386966A1 (en) * | 2002-07-24 | 2004-02-04 | Libragen | Method for the expression of unknown environmental DNA into adapted host cells |
| US6864087B2 (en) * | 2001-07-31 | 2005-03-08 | Wisconsin Alumni Research Foundation | Method for converting single-copy BAC vectors to conditional high-copy pBAC/oriHC vectors |
| EP1448773A4 (en) * | 2001-11-15 | 2006-07-05 | Aventis Pharma Inc | Genetically modified bacterial strains and novel vectors for use in expressing and assaying natural products |
| WO2016180379A1 (en) * | 2015-05-14 | 2016-11-17 | Universidad De Los Andes | Novel transposon that promotes the functional expression of genes in episomal dna, and method for increasing dna transcription in the functional analysis of metagenomic libraries |
| US11319579B2 (en) | 2014-11-18 | 2022-05-03 | OriCiro Genomics, Inc. | Method of amplifying circular DNA |
| US11685940B2 (en) | 2017-02-28 | 2023-06-27 | Moderna Enzymatics Co., Ltd. | Method of replicating or amplifying circular DNA |
| US12157915B2 (en) | 2016-05-17 | 2024-12-03 | Moderna Enzymatics Co., Ltd. | Method of amplifying circular DNA |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118667848B (en) * | 2024-05-31 | 2025-07-25 | 云舟生物科技(广州)股份有限公司 | Plasmid skeleton capable of improving stability of poly A tail |
-
2000
- 2000-06-16 IL IL14712500A patent/IL147125A0/en unknown
- 2000-06-16 AU AU54966/00A patent/AU5496600A/en not_active Abandoned
- 2000-06-16 KR KR1020017016220A patent/KR20020011139A/en not_active Withdrawn
- 2000-06-16 EP EP00939961A patent/EP1196613A1/en not_active Withdrawn
- 2000-06-16 WO PCT/US2000/016767 patent/WO2000078977A1/en not_active Ceased
- 2000-06-16 BR BR0011765-0A patent/BR0011765A/en not_active IP Right Cessation
- 2000-06-16 JP JP2001505717A patent/JP2003503029A/en active Pending
- 2000-06-16 NZ NZ515502A patent/NZ515502A/en unknown
- 2000-06-16 MX MXPA01012406A patent/MXPA01012406A/en unknown
- 2000-06-16 CA CA002375821A patent/CA2375821A1/en not_active Abandoned
-
2001
- 2001-11-15 ZA ZA200109441A patent/ZA200109441B/en unknown
- 2001-12-17 NO NO20016153A patent/NO20016153L/en not_active Application Discontinuation
Non-Patent Citations (4)
| Title |
|---|
| IOANNOU P A ET AL: "A NEW BACTERIOPHAGE P1-DERIVED VECTOR FOR THE PROPAGATION OF LARGE HUMAN DNA FRAGMENTS", NATURE GENETICS,US,NEW YORK, NY, vol. 6, 1994, pages 84 - 89, XP000770742, ISSN: 1061-4036 * |
| OSUSKY MILAN ET AL: "Vectors with the fd replicon for in vivo cloning and analysis of genes.", GENE (AMSTERDAM), vol. 151, no. 1-2, 1994, pages 103 - 108, XP002149093, ISSN: 0378-1119 * |
| SHASHIKANT C S L ET AL: "Recombinogenic targeting: a new approach to genomic analysis-a review", GENE,NL,ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 223, no. 1-2, 26 November 1998 (1998-11-26), pages 9 - 20, XP002149156, ISSN: 0378-1119 * |
| SHIZUYA H ET AL: "CLONING AND STABLE MAINTENANCE OF 300-KILOBASE-PAIR FRAGMENTS OF HUMAN DNA IN ESCHERICHIA COLI USING AN F-FACTOR-BASED VECTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 89, 1 September 1992 (1992-09-01), pages 8794 - 8797, XP000573603, ISSN: 0027-8424 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6864087B2 (en) * | 2001-07-31 | 2005-03-08 | Wisconsin Alumni Research Foundation | Method for converting single-copy BAC vectors to conditional high-copy pBAC/oriHC vectors |
| EP1448773A4 (en) * | 2001-11-15 | 2006-07-05 | Aventis Pharma Inc | Genetically modified bacterial strains and novel vectors for use in expressing and assaying natural products |
| EP1386966A1 (en) * | 2002-07-24 | 2004-02-04 | Libragen | Method for the expression of unknown environmental DNA into adapted host cells |
| WO2004013327A1 (en) * | 2002-07-24 | 2004-02-12 | Libragen | Method for the expression of unknown environmental dna into adapted host cells |
| US7910522B2 (en) | 2002-07-24 | 2011-03-22 | Libragen | Method for the expression of unknown environmental DNA into adapted host cells |
| US11319579B2 (en) | 2014-11-18 | 2022-05-03 | OriCiro Genomics, Inc. | Method of amplifying circular DNA |
| WO2016180379A1 (en) * | 2015-05-14 | 2016-11-17 | Universidad De Los Andes | Novel transposon that promotes the functional expression of genes in episomal dna, and method for increasing dna transcription in the functional analysis of metagenomic libraries |
| US11155822B2 (en) | 2015-05-14 | 2021-10-26 | Universidad De Los Andes | Transposon that promotes functional DNA expression in episomal DNAs and method to enhance DNA transcription during functional analysis of metagenomic libraries |
| US12157915B2 (en) | 2016-05-17 | 2024-12-03 | Moderna Enzymatics Co., Ltd. | Method of amplifying circular DNA |
| US11685940B2 (en) | 2017-02-28 | 2023-06-27 | Moderna Enzymatics Co., Ltd. | Method of replicating or amplifying circular DNA |
| US12157907B2 (en) | 2017-02-28 | 2024-12-03 | Moderna Enzymatics Co., Ltd. | Method of replicating or amplifying circular DNA |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1196613A1 (en) | 2002-04-17 |
| NO20016153D0 (en) | 2001-12-17 |
| ZA200109441B (en) | 2003-04-30 |
| NZ515502A (en) | 2004-08-27 |
| JP2003503029A (en) | 2003-01-28 |
| IL147125A0 (en) | 2002-08-14 |
| MXPA01012406A (en) | 2002-06-04 |
| BR0011765A (en) | 2002-03-05 |
| AU5496600A (en) | 2001-01-09 |
| NO20016153L (en) | 2002-02-15 |
| KR20020011139A (en) | 2002-02-07 |
| CA2375821A1 (en) | 2000-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7138267B1 (en) | Methods and compositions for amplifying DNA clone copy number | |
| JP4303597B2 (en) | Construction of novel strains containing minimized genomes by Tn5-binding Cre / loxP excision system | |
| JP4264703B2 (en) | Synthetic genes and bacterial plasmids lacking CpG | |
| CN100420747C (en) | Method for producing insertional mutations | |
| EP0927258B1 (en) | System for in vitro transposition using modified tn5 transposase | |
| CN103068995B (en) | direct clone | |
| CN106119269B (en) | Method for preparing linear single-stranded DNA in escherichia coli | |
| EP1227147A2 (en) | Recombinational cloning using engineered recombination sites | |
| JP2021512617A (en) | Genome editing using CRISPR in Corynebacterium | |
| CN102703424A (en) | Method for recombination-mediated escherichia coli genome point mutation | |
| Krabbe et al. | Inactivation of the replication‐termination system affects the replication mode and causes unstable maintenance of plasmid R1 | |
| EP1196613A1 (en) | Novel vectors for improving cloning and expression in low copy number plasmids | |
| US6248569B1 (en) | Method for introducing unidirectional nested deletions | |
| US7592161B2 (en) | Methods for analyzing the insertion capabilities of modified group II introns | |
| US10920189B2 (en) | Genome-wide rationally-designed mutations leading to enhanced lysine production in E. coli | |
| EP1240339A1 (en) | Double selection vector | |
| US6818441B1 (en) | Vectors for improving cloning and expression in low copy number plasmids | |
| EP1924693B1 (en) | Hybrid portable origin of replication plasmids | |
| Feinbaum | Introduction to plasmid biology | |
| US20030027286A1 (en) | Bacterial promoters and methods of use | |
| US8999672B2 (en) | Compositions and processes for improved plasmid DNA production | |
| US20100323400A1 (en) | Compositions and Methods for Controlling Copy Number for a Broad Range of Plasmids and Uses Thereof | |
| McGregor | Transposon and transposome mutagenesis of plasmids, cosmids, and BACs | |
| EP3960862A1 (en) | Rna-aptamer-sensors | |
| WO2026022530A1 (en) | A genetic tool for engineering the genome of bacteria and a method of preparing the same there of |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 515502 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/012406 Country of ref document: MX |
|
| ENP | Entry into the national phase |
Ref document number: 2375821 Country of ref document: CA Ref document number: 2375821 Country of ref document: CA Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/1752/CHE Country of ref document: IN |
|
| ENP | Entry into the national phase |
Ref document number: 2001 505717 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 54966/00 Country of ref document: AU Ref document number: 1020017016220 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2000939961 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020017016220 Country of ref document: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 2000939961 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2000939961 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017016220 Country of ref document: KR |